Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
The company has reported total income of Rs. 704.5 crores during the period ended June 30, 2023
The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023
The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
DeltaV control system natively integrated into Sartorius Biostat STR bioreactors provide a foundation for semi-autonomous operations and up to 80% less integration time
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023
Aims to foster a Resilient and Sustainable Healthcare Ecosystem
Subscribe To Our Newsletter & Stay Updated